The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
Open Access
- 31 May 2022
- journal article
- research article
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 37 (2) , 177-184
Abstract
Background: Anticoagulation during extracorporeal membrane oxygenation (ECMO) usually is required to prevent thrombosis. The aim of this study was to investigate the usefulness of nafamostat mesilate (NM) as a regional anticoagulant during veno-arterial ECMO (VA-ECMO) treatment. Methods: We retrospectively reviewed the medical records of 16 patients receiving VA-ECMO and NM from January 2017 to June 2020 at Haeundae Paik Hospital. We compared clinical and laboratory data, including activated partial thromboplastin time (aPTT), which was measured simultaneously in patients and the ECMO site, to estimate the efficacy of regional anticoagulation. Results: The median patient age was 68.5 years, and 56.3% of patients were men. Cardiovascular disease was the most common primary disease (75.0%) requiring ECMO treatment, followed by respiratory disease (12.5%). The median duration of ECMO treatment was 7.5 days. Among 16 patients, seven were switched to NM after first using heparin as an anticoagulation agent, and nine received only NM. When comparing aPTT values in the NM group between patients and the ECMO site, that in patients was significantly lower than that at the ECMO site (73.57 vs. 79.25 seconds; P=0.010); in contrast, no difference was observed in the heparin group. Conclusions: NM showed efficacy as a regional anticoagulation method by sustaining a lower aPTT value compared to that measured at the ECMO site. NM should be considered as a safer regional anticoagulation method in VA-ECMO for patients at high risk of bleeding.Keywords
This publication has 28 references indexed in Scilit:
- Extracorporeal Membrane Oxygenation—Hemostatic ComplicationsTransfusion Medicine Reviews, 2015
- Extracorporeal Membrane Oxygenation in the AdultAnesthesia & Analgesia, 2014
- Nafamostat Mesilate for Anticoagulation in Continuous Renal Replacement TherapyThe International Journal of Artificial Organs, 2013
- The Role of Nafamostat Mesylate in Continuous Renal Replacement Therapy among Patients at High Risk of BleedingRenal Failure, 2012
- Nafamostat Mesilate as an Anticoagulant during Continuous Veno-Venous Hemodialysis: A Three-Year Retrospective Cohort StudyThe International Journal of Artificial Organs, 2011
- Anticoagulation and Coagulation Management for ECMOSeminars in Cardiothoracic and Vascular Anesthesia, 2009
- Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activityThrombosis Research, 1994
- Inhibitory Effect of a New Synthetic Protease Inhibitor (FUT-175) on the Coagulation SystemPathophysiology of Haemostasis and Thrombosis, 1985
- Pharmacological Studies of FUT-175, Nafamstat Mesilate I. Inhibition of Protease Activity in in Vitro and in Vivo ExperimentsThe Japanese Journal of Pharmacology, 1984
- Effects of FUT-175, a New Synthetic Protease Inhibitor on Endotoxin-Induced Disseminated Intravascular Coagulation in RatsPathophysiology of Haemostasis and Thrombosis, 1983